125 related articles for article (PubMed ID: 8495276)
1. Potency ratio--a brief synopsis.
Avioli LV
Br J Rheumatol; 1993 May; 32 Suppl 2():24-6. PubMed ID: 8495276
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
Olgaard K; Storm T; van Wowern N; Daugaard H; Egfjord M; Lewin E; Brandi L
Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
Aicardi G; Benso L; Vignolo M; Terragna A; Verrina E; Cordone G; Coppo R; Sernia O; Sardella ML; Di Battista E
Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
[TBL] [Abstract][Full Text] [Related]
4. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
Rizzato G; Riboldi A; Imbimbo B; Torresin A; Milani S
Respir Med; 1997 Sep; 91(8):449-60. PubMed ID: 9338047
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of glucocorticoids on calcium absorption and bone mass.
Gennari C
Br J Rheumatol; 1993 May; 32 Suppl 2():11-4. PubMed ID: 8495275
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
Scudeletti M; Puppo F; Lanza L; Mantovani L; Bosco O; Iudice A; Imbimbo B; Indiveri F
Eur J Clin Pharmacol; 1993; 45 Suppl 1():S29-34. PubMed ID: 8313931
[TBL] [Abstract][Full Text] [Related]
7. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
[TBL] [Abstract][Full Text] [Related]
8. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
Aicardi G; Milani S; Imbimbo B; Vignolo M; Di Battista E; Gusmano R; Terragna A; Cordone G; Cottafava F; Coppo R
Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
[TBL] [Abstract][Full Text] [Related]
9. Deflazacort induced stronger immunosuppression than expected.
Gonzalez-Castañeda RE; Castellanos-Alvarado EA; Flores-Marquez MR; Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
[TBL] [Abstract][Full Text] [Related]
10. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
Broyer M; Terzi F; Lehnert A; Gagnadoux MF; Guest G; Niaudet P
Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
[TBL] [Abstract][Full Text] [Related]
11. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Morabito F; Callea I; Irrera G; Cartisano G; Dattola A; Rodinò A; Brugiatelli M
Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
[TBL] [Abstract][Full Text] [Related]
12. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.
Di Munno O; Imbimbo B; Mazzantini M; Milani S; Occhipinti G; Pasero G
J Rheumatol; 1995 Aug; 22(8):1492-8. PubMed ID: 7473472
[TBL] [Abstract][Full Text] [Related]
13. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica.
Lund B; Egsmose C; Jørgensen S; Krogsgaard MR
Calcif Tissue Int; 1987 Dec; 41(6):316-20. PubMed ID: 3124940
[TBL] [Abstract][Full Text] [Related]
14. Deflazacort in juvenile chronic arthritis.
Loftus JK; Reeve J; Hesp R; David J; Ansell BM; Woo PM
J Rheumatol Suppl; 1993 Apr; 37():40-2. PubMed ID: 8501751
[TBL] [Abstract][Full Text] [Related]
15. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
[TBL] [Abstract][Full Text] [Related]
16. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
18. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.
Parente L
BMC Pharmacol Toxicol; 2017 Jan; 18(1):1. PubMed ID: 28057083
[TBL] [Abstract][Full Text] [Related]
19. Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity.
Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
Adv Ther; 2007; 24(5):1052-60. PubMed ID: 18029332
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]